Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder

S. Potvin, T. Pampoulova, A. Mancini-Marië, O. Lipp, R. H. Bouchard, E. Stip

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Abstract

Few data have been gathered about the impact of psychoactive substances on extrapyramidal symptoms (EPS) in schizophrenia, and so far, inconsistent results have been reported. We studied 41 outpatients with schizophrenia (based on DSM-IV criteria), who were divided into two groups: with (n = 17) and without (n = 24) a substance use disorder (alcohol, cannabis, and/or cocaine). Both groups were matched for sociodemographic data and psychiatric symptoms (Positive and Negative Syndrome Scale). EPS were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale, and all patients were stable on either quetiapine or clozapine. Patients receiving anti-cholinergic drugs were excluded. Analyses of variance were conducted on both groups and showed that schizophrenia patients with a comorbid substance use disorder (especially cocaine) displayed more EPS compared with non-abusing patients.

Original languageEnglish
Pages (from-to)796-798
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume77
Issue number6
DOIs
Publication statusPublished - Jun 2006
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder'. Together they form a unique fingerprint.

Cite this